NeoGenomics, Inc.
WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
64049M209
SEDOL
2598246
CIK
0001077183
www.neogenomics.com
LEI:
FIGI: BBG000BKH263
NEO
NeoGenomics, Inc.
GICS: -
·
Sector: Healthcare
·
Sub-Sector: Diagnostics & Research
NAME
NeoGenomics, Inc.
ISIN
US64049M2098
TICKER
NEO
MIC
XNAS
REUTERS
NEO.OQ
BLOOMBERG
NEO US
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Mon, 06.01.2025
NeoGenomics
US64049M2098
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. Chris Smith, Chief Executive Officer, will deliver a presentation followed by Q&A on Wednesday, January 15, at 1:30 p.m. PT/4:30 p.m. ET.
The presentation will be webcast li...
NeoGenomics
Wed, 11.12.2024
NeoGenomics
US64049M2098
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, announced the recent publication of a new study in ESMO Open, demonstrating how circulating tumor DNA (ctDNA) in monitoring molecular residual disease (MRD) may enable earlier identification of disease recurrence for high-risk melanoma patients.
Melanoma impacted over ...
NeoGenomics
Mon, 09.12.2024
NeoGenomics
US64049M2098
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will share its latest research on hematologic malignancies and the prognostic effects of microenvironment signatures in primary central nervous system (CNS) lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting, booth #2347, in San Diego, December 7-10...
NeoGenomics
Tue, 19.11.2024
NeoGenomics
US64049M2098
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will present four abstracts at the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo in Vancouver, Canada, November 19-23 (booth #830). The research demonstrates how ctDNA and next-generation sequencing (NGS) can drive more personalized and accurat...
NeoGenomics
Thu, 14.11.2024
NeoGenomics
US64049M2098
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced the appointment of Felicia Williams to its Board of Directors.
“We are fortunate to welcome Felicia Williams to our board of directors, bringing her experience across the spectrum of finance, accounting, audit, and enterprise risk management to NeoGenom...
NeoGenomics
Fri, 08.11.2024
NeoGenomics
US64049M2098
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will attend the Piper Sandler 36th Annual Healthcare Conference. Members of the management team will participate in an in-person fireside chat on Thursday, Dec. 5, 2024, at 9:30 a.m. ET in New York City.
The presentation will be webcast live and accessible online via th...
NeoGenomics
Tue, 05.11.2024
NeoGenomics
US64049M2098
NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading oncology testing services company, today announced its third-quarter results for the period ended September 30, 2024.
Third Quarter 2024 Highlights As Compared To Third Quarter 2023
Consolidated revenue increased 10% to $168 million
Clinical Services revenue increased 14% to...
NeoGenomics
Tue, 22.10.2024
NeoGenomics
US64049M2098
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that the New York State Department of Health (NYSDOH) has granted the company conditional approval for its Neo Comprehensive Solid Tumor assay and NeoTYPE® DNA & RNA Lung, allowing for immediate commercial access in the state of New York. These next-g...
NeoGenomics
Tue, 15.10.2024
NeoGenomics
US64049M2098
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its third quarter 2024 financial results prior to the open of the U.S. financial markets on Tuesday, Nov. 5, 2024. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highl...
NeoGenomics
Tue, 08.10.2024
NeoGenomics
US64049M2098
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, announced today the launch of AML Express, a next-generation sequencing (NGS) assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia (AML).
“AML Express enhances our hematologic portfolio by addressing the clinical need...
NeoGenomics
Information on product placements
SMART * AD
P R O D U C T S U G G E S T I O N S
